RaySearch Laboratories AB (publ) announces that The University of New Mexico Comprehensive Cancer Center (UNMCCC) has placed an order for the treatment planning system RayStation®* through a public tender process.

To meet the high patient demand and bring new technologies to the patients UNMCCC is expanding its clinical radiation oncology services. The purchase of RayStation is part of this investment and will replace the center’s current treatment planning system. The order includes new and advanced technology, such as adaptive planning and machine learning techniques for automated contouring.

Alan Tomkinson, UNMCCC Interim Director and CEO, says: “Our patients deserve the best. This new technology will enable us to serve more New Mexicans better.”
Johan Löf, founder and CEO, RaySearch, says: “There are only a few Request For Proposals in the United States, and it is gratifying when we win these, which are based on objective measures. We look forward to a long and successful relationship with the University of New Mexico Comprehensive Cancer Center and to contributing to advanced technology in the care for the hospital’s patients.”


About University of New Mexico
The University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius. Its 146 board-certified oncology specialty physicians include cancer surgeons in every specialty (abdominal, thoracic, bone and soft tissue, neurosurgery, genitourinary, gynecology, and head and neck cancers), adult and pediatric hematologists/medical oncologists, gynecologic oncologists, and radiation oncologists. They, along with more than 600 other cancer healthcare professionals (nurses, pharmacists, nutritionists, navigators, psychologists and social workers), provide treatment to 65% of New Mexico’s cancer patients from all across the state and partner with community health systems statewide to provide cancer care closer to home. They treated approximately 13,000 patients in more than 100,000 ambulatory clinic visits in addition to in-patient hospitalizations at UNM Hospital. A total of nearly 1300 patients participated in cancer clinical trials, 40% of whom participated in clinical trials testing new cancer treatments that include tests of novel cancer prevention strategies and cancer genome sequencing. The more than 100 cancer research scientists affiliated with the UNMCCC were awarded $36.2 million in federal and private grants and contracts for cancer research projects. Since 2015, they have published nearly 1000 manuscripts, and promoting economic development, they filed 136 new patents and launched 10 new biotechnology start-up companies. Finally, the physicians, scientists and staff have provided education and training experiences to more than 500 high school, undergraduate, graduate, and postdoctoral fellowship students in cancer research and cancer health care delivery.

Health IT Homepage